Interestingly, a [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy could also allow a successful response to radionuclide therapy while minimizing xerostomia severity [82,83,84]. This evidence concerns the gene FOLH1 and xerostomia.